News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Cancer Drug Coveted By Pfizer Inc. (PFE) Works In Trial


5/15/2014 7:43:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc (AZN) said an experimental cancer drug shrank tumors in half of patients in an early-stage study, a result that may help its case that Pfizer Inc. (PFE)’s takeover bid substantially undervalues the company. The drug, called AZD9291, is designed to help patients with a gene mutation found in 15 percent of Caucasian patients with non-small cell lung cancer, and 40 percent of Asians. If approved, it could generate more than $2.2 billion by 2025, said Seamus Fernandez, a Leerink Partners analyst in Boston.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters
Read at The Street.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES